Recruiting PHASE3 INTERVENTIONAL 2-arm
NCT07328841
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
Reduced-Dose Versus Conventional-Dose Intensity-Modulated Radiation Therapy in Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy: A Multicenter, Phase III Clinical Trial
Sponsor: Ming-Yuan Chen
Conditions
Nasopharyngeal Carcinoma (NPC)
Interventions
Cisplatin-based induction chemotherapy Concurrent Chemotherapy Full course of PD-1blockades Reduced-dose radiotherapy Standard-dose radiotherapy
Updated 1 time since 2026 Last updated: Dec 27, 2025 Started: Nov 18, 2025 Primary completion: Jun 30, 2030 Completion: Jun 30, 2032
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE3 trial investigates Nasopharyngeal Carcinoma (NPC) and is currently actively recruiting participants. Ming-Yuan Chen leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Ming-Yuan Chen
Data source: Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .